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To the Editor
In the letter by Tan et al,1 in response to the updated US Public Health Service (PHS) 
guidelines,2 several issues are raised for consideration by institutions when developing their 
protocols for occupational exposures to human immunodeficiency virus (HIV). We 
emphasize that the US PHS guidelines are not intended to be used as a strict protocol; they 
are open to interpretation and modification, based on local circumstances. The PHS working 
group and expert consultant panel used available scientific evidence and expert opinion as 
the basis for developing the updated guidelines. However, evidence of superior efficacy of a 
single PEP regimen among the preferred and alternatives2 does not exist and is unlikely to 
be developed. Demonstrating differential efficacy among PEP regimens that likely possess a 
similar ability to prevent infection is limited by both the low HIV transmission rate 
associated with occupational exposures as well as the ethical considerations associated with 
conducting a randomized controlled trial in that setting. Thus, most of the opinion expressed 
in the guideline was based on relevant but indirect evidence. The expert panel believed that 
the regimen adherence advantages of a raltegravir (RAL)-based regimen offered a slight 
benefit over similar regimens containing protease inhibitors. An optimal single PEP regimen 
for occupational exposures has not been demonstrated and, given the constraints noted 
above, likely never will be.
We agree that evidence of PEP tolerability and adherence are among the factors that should 
inform PEP regimen choices. Tan et al1 describe clinical outcome data1,3–5 among RAL- 
and lopinivir/ritonavir-based PEP regimen recipients who primarily experienced 
nonoccupational exposures. Though the authors suggest roughly comparable outcomes, we 
interpret these data differently. The 15% higher average regimen completion rate among 
RAL-based PEP regimen recipients seems to indicate a slight advantage of RAL-based PEP. 
We nonetheless recommend caution when extrapolating from data describing primarily 
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nonoccupational PEP recipients to the occupational setting. Historically, healthcare 
personnel taking occupational PEP have reported much higher rates of regimen intolerance 
than persons taking these agents for either nonoccupational exposures or as treatment for 
infection;6 thus, one might expect different PEP completion rates between nonoccupational 
and occupational exposure populations.
Tan et al1 question the benefit of the minimal drug interactions afforded by RAL-based PEP 
regimens and indicate that significant polypharmacy is uncommon among their PEP 
recipients. Minimizing the risk for drug interactions can increase medication adherence and 
acceptance. Taking even a single medication (either prescription or over the counter) while 
receiving PEP can place a PEP recipient at risk for significant drug interactions. Because 
RAL can be administered with proton pump inhibitors, H2 blockers, antidepressants, and 
oral contraceptives, all of which are commonly used by relatively healthy personnel, we 
believe that RAL-based regimens might have a relative advantage. PEP regimen adherence 
rarely exceeds 85% in most published studies, suggesting that adherence remains a 
significant issue. Thus, addressing factors that can improve adherence is likely to increase 
effectiveness.
The commentary authors suggest caution with the use of the tenofovir, emtricitabine, and 
RAL regimen as PEP for exposures to source patients known or suspected to harbor viruses 
resistant to nucleotide reverse-transcriptase inhibitors. We agree—and the guidelines 
indicate—that special considerations should be given to circumstances in which exposure to 
resistant virus is likely. Expert consultation is recommended for exposures to known or 
suspected drug-resistant HIV to ensure that drugs to which the source virus is unlikely to be 
resistant are prescribed as PEP.2 The relevance of RAL’s modest genetic barrier to 
resistance in the treatment of HIV infection may not be directly applicable to the success of 
PEP. PEP efficacy data remain too limited to indicate whether or how genetic barriers to 
resistance influence HIV PEP outcomes.
Tan et al1 question whether simplification of clinical decision making by eliminating 
exposure risk stratification may be less relevant to occupational PEP and suggest that 
occupational exposures are often managed in institutional corporate health clinics by expert 
occupational health providers. Occupational health clinics may provide management for 
exposures that occur in outpatient and inpatient settings when exposures occur during the 
daytime hours during which occupational health clinics are typically open. However, such 
occupational health clinics are unlikely to be available for individuals sustaining exposures 
outside these normal clinic hours. For facilities that provide 24-hour patient care—such as 
acute care hospitals, long-term acute care hospitals, skilled nursing facilities, and emergency 
treatment centers—occupational exposures to bloodborne pathogens occur at all hours of the 
day. Our experience suggests that after-hours exposures are often managed in emergency 
rooms or stand-alone clinics, and physicians in these settings may be less familiar with the 
approaches to exposure management and pharmacologic agents for prophylaxis.
Finally, we agree with Tan et al1 that medication cost is an important consideration, and the 
guidelines indicate that a more cost-efficient alternative to RAL may be required.2 
Individual facilities should consider undertaking comparative cost-benefit analyses—
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emphasizing factors that improve PEP adherence and minimize toxicities—when updating 
institutional PEP policies and protocols. The guidelines list several alternative medications 
for PEP regimens.2
Other experts are in agreement with PHS on a preference for RAL-based occupational PEP.7 
Given the limited data available on PEP administration, efficacy, and failures, some experts 
may disagree, and reasonable arguments can be made to support different conclusions. We 
echo the call for publication of relevant PEP data to inform regimen decisions. While such 
data are unlikely to coalesce around a single optimal regimen, electronic publication of this 
guideline is intended to allow for prompt updates when additional data become available.
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